LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates

• Expanded agreement grants Iksuda access to Legochem Biosciences’ next generation ADC platform for up to six targets • Iksuda also gains access to LegoChem Biosciences’ new payload, supplementing the tumour-activated payloads accessed in 2020

NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia

Randomized embedded multi-factorial platform trial to provide accelerated, real-world evidence in community acquired pneumonias including COVID-19, influenzas and bacterial pneumonias

CEO Update | 21 June 2021

Following the Prime Minister’s announcement last Monday that COVID-19 restrictions were to be extended by a further four weeks in England, we have taken the difficult decision to postpone the BIA’s Garden Party. We hope to hold the event in person in September and we will share details once the new arrangements with the venue have been confirmed.

Covington Advises Arecor Therapeutics on AIM IPO

LONDON, June 17, 2021 – Covington advised Arecor Therapeutics plc on the admission of its shares to trading on the AIM market of the London Stock Exchange. The IPO raised gross proceeds of £20 million through an oversubscribed placing of ordinary shares giving the company a market capitalisation of approximately £62.5 million.

The public strongly agree that patients living with a rare disease should be able to equally access medicines on the NHS, new report reveals

The BIA has today launched a report Public attitudes to Rare Diseases: The case for equal access which presents the findings of a survey commissioned by the BIA on public attitudes towards rare diseases and access to medicine.

Discovery Park announces appointment to new role of Chief Business Officer

Sandwich, Kent, June 15 2021 – Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing life sciences companies, is pleased to announce the appointment of science park expert Jane Kennedy to the new role of Chief Business Officer (CBO).

Experienced regulatory professionals join the Boyds team

Leading pharmaceutical and biotech product development consultancy Boyds has added to its regulatory team with the appointments of Shalini Gupta and Sarah Stevenson in response to recent growth and the continued increase in demand for its dedicated regulatory services.

CEO update | 14 June 2021

I was delighted to read on Friday night that many colleagues and BIA members were rightly recognised in the Queen’s Birthday Honours List 2021. The headlines were dominated by Kate Bingham, former Chair of the UK’s Vaccine Taskforce (VTF) and Professor Sarah Gilbert of Oxford University who both became Dames.

Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

• ETD001 is a novel inhaled, long-acting ENaC inhibitor • Therapy applicable to all cystic fibrosis patients, independent of genotype

Instrumental figures in UK COVID-19 vaccine development recognised in Queen’s Birthday Honours 2021

The Queen’s Birthday Honours 2021 has been released with several UK biotech and life sciences figures receiving honours for their contributions to the UK’s response to the COVID-19 pandemic. Those receiving honours include: Kate Bingham, former Chair of the UK Vaccine Taskforce (VTF), has received a damehood Ian McCubbin, former Vaccine Manufacturing expert on the VTF, former VP of global supply for GSK and former chair of the BIA’s COVID-19 Vaccine Manufacturing Taskforce, has received a CBE Annette England (Netty), bioprocessing consultant for the BIA, has received an MBE